






	Risk Factor	Score		Risk Factor	Score
С	Congestive Heart Failure	1	н	Hypertension	1
円	Hypertension	1	A	Abnormal renal or liver	1 or 2
(A)	Age > 75 years	2	_	function (1 each)	
	Diabetes Mellitus	1	(S)	Stroke	1
S,	Stroke/TIA/TE	2	В	Bleeding	1
\odot	Vascular Disease	1	L	Labile INR	1
Α	Age 65 – 74 years	1	E	Elderly Age (>65 years)	1
ଚ୍ଚ	Female	1	D	Drugs or alcohol (1 each)	1 or 2
	Maximum Score	9		(antiplatelet, NSAIDS)	
				Maximum Score	9

























Мо	st Stud	ied L	AAC	Devic	e	+	
		PROTECT AF	CAP Registry	PREVAIL	CAP2 Registry	Totals	
	Enrollment	2005-2008	2008-2010	2010-2012	2012-2014	\frown	
	Enrolled	800	566	461	579	2406	
	Randomized	707		407		1114	
	WATCHMAN: warfarin (2:1)	463 : 244	566	269 :138	579	1877: 382	
	Mean Follow-up (years)	4.0	3.7	2.2	0.58	N/A	
	Patient-years	2717	2022	860	332	5931	











C1		Wayne N. Leimbach, Jr., MD Robert E. Lynch, MD Robert C. Sensenschein, MD	Oklahoma Heart Institute
Sha	ared Decision Atrial Fib	James J. Nerner, MD	
But some peor '	llation have an increased risk of str	Gregory D. Johnson, MD Alan M. Kanoshige, MD Edward T. Martin, MD Roger D. Des Parz, MD	
This guide wil For most people, blood t	Talk to your doctor abou Based on your age, sex, and me	Raj H. Chandsaney, MD David A. Sandiar, MD Frank J. Gaffney, MD	January 12, 2018
How much dej	Your risk of stroke in the next :	litic G. Aasthach, MD Boberi L. Smith, Jr., MD Cosig S. Cameron, MD	BE-
Blood thinners can also	That means if 100 people with expected to have a stroke in the	Eugene J. Ichinose, MD John S. Tulloch, MD Anthony W. Haney, MD Douatas A. Davies, MD	Dr. Sandler,
 Some people I they have. 	Based on your _high_% risk c . Not taking a blood thim	Nitl Agneval, MD Kamran I. Mahammad, MD Arash Kamaras, DO	Mrs. is a very pleasant <u>65 year old</u> female with paroxysmal atrial fibrillation and a history of gastrointestinal bleed.
There is no one decision The choice dependence of the matters to you This guide will	Taking a blood thinner. Other recommendations	Viewer Y. Cheng, MD Statiny K. Zimmerman, MD Mathew B. Good, DO Stephen C. Dabatic, MD Stephen C. Badriguer, MD Stendra E. Badriguer, MD steeptor. J. URIX, 2012	Given his elevated risk of stroke (CHADS2 = 3- age, female, <u>http</u>) she qualifies for <u>thromboprophytax</u> . In light of his history <u>of gastrointestinal</u> bleed and elevated risk of bleeding (HASUELD = 2 - age, and previous bleed) she is a suboptimal candidate for long-term anticoagulation.
	Patient Signature	David A. LUE MD	According to FDA guidelines for shared decision with Mrs. and I have had conversations for stroke prevention. Knowing that she is at an elevated risk
	Print Name	Michael R. Philips, MD Edward J. Colomas, MD John M. Weber, MD	for stroke it would be in her best interest to proceed with the left atrial appendage closure procedure for future stroke prevention.
		Endocrinology Christian S. Hanson, DO D. Esik Aspenson, MD	Sincerely,
		Kally R. Enser, MD Cristia N. Brans, MD Ralph J. Duda, Jr., MD	Alan Kaneshire, MD





Which of the following patients is NOT a candidate for Watchman LAA Closure?


- $A.\,65$ yo woman with persistent AF, HTN, prior TIA, and recurrent GI bleeding on apixaban (Eliquis).
- $B.\ 80$ yo man with permanent AF, HTN, DM, CHF, and frequent falls on chronic warfarin.
- C. 50 yo police officer with parox AF, HTN, DM on rivaroxaban (Xarelto) concerned about his occupational bleeding risk.
- D. 65 yo woman with permanent AF, HTN, DM, prior CVA, and recurrent, spontaneous intracranial hemorrhage - deemed not to be a candidate for any anticoagulation (absolute contraindication per neurosurgery).


Which of the following patients is NOT a candidate for Watchman LAA Closure?


- A. 65 yo woman with persistent AF, HTN, prior TIA, and recurrent GI bleeding on apixaban (Eliquis).
- B. 80 yo man with permanent AF, HTN, DM, CHF, and frequent falls on chronic warfarin.
- C. 50 yo police officer with parox AF, HTN, DM on rivaroxaban (Xarelto) concerned about his occupational bleeding risk.
- D. 65 yo woman with permanent AF, HTN, DM, prior CVA, and recurrent, spontaneous intracranial hemorrhage - deemed not to be a candidate for any anticoagulation (absolute contraindication per neurosurgery).


What do you mean, "Watchman patients must be suitable for warfarin?!?!?"














ASAP-TOO Trial

- Randomized 2:1 (WATCHMAN:Control) IDE trial in NVAF subjects deemed unsuitable for anticoagulation
- Control group: Single antiplatelet medication or no medication
- Up to 888 subjects
- Primary effectiveness endpoint: Time to first event of ischemic stroke or systemic embolism
- Primary safety endpoint: 7-day combined rate of death, ischemic stroke, systemic embolism and complications requiring major cardiovascular or endovascular intervention.

Adequately powered to address the fundamental question of benefit-risk in patients who would otherwise not be treated with anticoagulation





Which of the following patients is the BEST candidate for Watchman LAA Closure?


- A. 65 yo woman with persistent AF, HTN, prior TIA, and recurrent GI bleeding on apixaban (Eliquis).
- $B.\,$ 80 yo man with permanent AF, HTN, DM, CHF, and frequent falls on chronic warfarin who lives in a nursing home.
- C. 50 yo man with HTN, DM, and paroxysmal AF tolerating apixaban (Eliquis) well who "wants to come off of his blood thinner."
- D. 65 yo woman with permanent AF, HTN, DM, prior CVA, and recurrent, spontaneous intracranial hermorrhage - deemed not to be a candidate for any anticoagulation (absolute contraindication per neurosurgery).

Which of the following patients is the BEST candidate for Watchman LAA Closure?

- A. 65 yo woman with persistent AF, HTN, prior TIA, and recurrent GI bleeding on apixaban (Eliquis).
- B. 80 yo man with permanent AF, HTN, DM, CHF, and frequent falls on chronic warfarin who lives in a nursing home.
- C. 50 yo man with HTN, DM, and paroxysmal AF tolerating apixaban (Eliquis) well who "wants to come off of his blood thinner."
- D. 65 yo woman with permanent AF, HTN, DM, prior CVA, and recurrent, spontaneous intracranial hemmorrhage - deemed not to be a candidate for any anticoagulation (absolute contraindication per neurosurgery).










There are known knowns. These are things we know that we know. There are known unknowns. That is to say, there are things that we know we don't know. But there are also unknown unknowns. There are things we don't know we don't know.

— Donald Rumsfeld —

Knowledge Gaps in LAAC "The Known Unknowns"

- Only prospective, randomized data for Watchman device.
 - Is antiplatelet therapy sufficient?
 - ASAP-TOO
- AMULET IDENo head-to-head comparisons:
- device vs. DOAC
 - device vs. device
- Safety of cardioversion without anticoagulation post-LAAC?





Summary


- Percutaneous left atrial appendage closure is here!
- Watchman device only randomized prospective data
 But stay tuned...
- Watchman LAAC candidates must be suitable for short-term anticoagulation.
 - Await ASAP-TOO and Amulet IDE studies
- The future looks bright...
















WATC	• Five studies, >2400 patients, nearly 6000 patient-years of follow-up CHMAN TM Clinical Leadership WATCHM Uar Annu. Aver CLOSURE DE	
	 WATCHMAN is a safe alternative to long-term warfarin therapy which offers comparable stroke risk reduction and enables patients to stop taking warfarin^{1,2} 	
	95% implant success rate ³	
	 >92% warfarin cessation after 45 days, >99% after 1 year¹ 	
	 WATCHMAN™ therapy demonstrated comparable stroke risk reduction and statistically superior reductions in major non-procedure related bleeding and cardiovascular death compared to warfarin²⁴: 	
	1. Henne, DIR et al. JACC 2014; Via AI, No. 1. 2. Henne, DIR et al. JACC 2010; Via 63, No. 2. 3. Rodaty VV; Hennes DIR et al. JACC 2016; Ardice in press. 4. Price, M. J., V. Y. Redaty, et al. JACC CV Interv XVII, RVII; 1025-1022	







Characteristic	PROTECT AF N=707	CAP N=566	PREVAIL N=407	CAP2 N=579	p-value		
CHADS ₂ Score	2.2 ± 1.2	2.5 ± 1.2	$\textbf{2.6} \pm \textbf{1.0}$	2.7 ± 1.1	<0.0001		
CHADS ₂ Risk Factors (% of Patients)							
CHF	26.9	23.3	19.1	27.1	0.004		
Hypertension	89.8	91.4	88.8	92.5	0.15		
Age ≥ 75	43.1	53.6	51.8	59.7	<0.001		
Diabetes	26.2	32.4	24.9	33.7	0.001		
Stroke/TIA	18.5	27.8	30.4	29.0	< 0.0001		
CHA2DS2-VASc	3.5 ± 1.6	3.9 ± 1.5	4.0 ± 1.2	4.5 ± 1.3	<0.0001		

